NEW YORK (GenomeWeb News) - Invitrogen said today it will buy primary cell provider CellzDirect for around $57 million in cash in an effort to expand its cellular analysis business.
 
CellzDirect’s human hepatocyte-based cell products and services are used in drug testing, particularly for predicting the effect of compounds on enzymatic metabolism in the liver.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.